Boundless Bio: designing cancer therapies around extrachromosomal DNA

Boundless Bio launches with $46M series A to tackle unexplored extrachromosomal DNA target space in cancer

With a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio is opening up a new target space in cancer by combining a commercially explored concept in tumor biology with President and CEO Zach Hornby’s expertise in precision medicine.

The San Diego-based company was founded

Read the full 514 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE